SRR1315019
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.564
- TNFA_SIGNALING_VIA_NFKB+0.554
- INTERFERON_GAMMA_RESPONSE+0.506
- IL6_JAK_STAT3_SIGNALING+0.485
- INFLAMMATORY_RESPONSE+0.465
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.456
- ANGIOGENESIS+0.453
- COAGULATION+0.414
- IL2_STAT5_SIGNALING+0.327
- ESTROGEN_RESPONSE_LATE+0.320
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- DNA_REPAIR-0.375
- PROTEIN_SECRETION-0.322
- MITOTIC_SPINDLE-0.318
- E2F_TARGETS-0.310
- MYC_TARGETS_V1-0.287
- MYC_TARGETS_V2-0.220
- G2M_CHECKPOINT-0.215
- PEROXISOME-0.178
- PI3K_AKT_MTOR_SIGNALING-0.064
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1455369 | GTEX | — | 0.940 |
| 2 | SRR1498550 | GTEX | — | 0.938 |
| 3 | SRR1489177 | GTEX | — | 0.934 |
| 4 | BS_PJPGVD62 | Ependymoma NOS | — | 0.930 |
| 5 | MNG663 | — | — | 0.924 |
| 6 | BS_W97QQYKQ | Ganglioglioma | — | 0.921 |
| 7 | sclc1896_S36.txt | — | cohortMD2 | 0.921 |
| 8 | BS_769BDPDB | pilocytic astrocytoma | — | 0.921 |
| 9 | SRR1470111 | GTEX | — | 0.917 |
| 10 | BS_S9929Z8B | Ganglioglioma | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.564 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.554 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.506 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.485 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.465 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.456 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.453 | Remibrutinib | — uncovered |
| COAGULATION | 0.414 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.327 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.319 | Inavolisib | — uncovered |
| APOPTOSIS | 0.318 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.308 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.302 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.292 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.289 | Temsirolimus | — uncovered |
| HYPOXIA | 0.281 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.279 | Inavolisib | — uncovered |
| MYOGENESIS | 0.278 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.256 | Inavolisib | — uncovered |